

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM548888

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Achaogen, Inc.		07/23/2019	Corporation:
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Cipla USA, Inc.		
<b>Street Address:</b>	10 Independence Boulevard		
<b>Internal Address:</b>	Suite 300		
<b>City:</b>	Warren		
<b>State/Country:</b>	NEW JERSEY		
<b>Postal Code:</b>	07059		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 5</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	87929555		
<b>Serial Number:</b>	87930012		
<b>Registration Number:</b>	5661889	ZEMDRI	
<b>Serial Number:</b>	87929654	ZEMDRI	
<b>Serial Number:</b>	87930066	ZEMDRI	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	3122076400		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	3122071000		
<b>Email:</b>	jnewman@reedsmith.com		
<b>Correspondent Name:</b>	Joshua W. Newman		
<b>Address Line 1:</b>	10 South Wacker Drive		
<b>Address Line 2:</b>	40th Floor		
<b>Address Line 4:</b>	Chicago, ILLINOIS 60606		
<b>NAME OF SUBMITTER:</b>	Joshua W. Newman		
<b>SIGNATURE:</b>	/Joshua W. Newman/		
<b>DATE SIGNED:</b>	11/11/2019		

OP \$140.00 87929555

**Total Attachments: 21**

source=Master Assignment Agreement [United States]#page1.tif  
source=Master Assignment Agreement [United States]#page2.tif  
source=Master Assignment Agreement [United States]#page3.tif  
source=Master Assignment Agreement [United States]#page4.tif  
source=Master Assignment Agreement [United States]#page5.tif  
source=Master Assignment Agreement [United States]#page6.tif  
source=Master Assignment Agreement [United States]#page7.tif  
source=Master Assignment Agreement [United States]#page8.tif  
source=Master Assignment Agreement [United States]#page9.tif  
source=Master Assignment Agreement [United States]#page10.tif  
source=Master Assignment Agreement [United States]#page11.tif  
source=Master Assignment Agreement [United States]#page12.tif  
source=Master Assignment Agreement [United States]#page13.tif  
source=Master Assignment Agreement [United States]#page14.tif  
source=Master Assignment Agreement [United States]#page15.tif  
source=Master Assignment Agreement [United States]#page16.tif  
source=Master Assignment Agreement [United States]#page17.tif  
source=Master Assignment Agreement [United States]#page18.tif  
source=Master Assignment Agreement [United States]#page19.tif  
source=Master Assignment Agreement [United States]#page20.tif  
source=Master Assignment Agreement [United States]#page21.tif

## INTELLECTUAL PROPERTY ASSIGNMENT

**THIS INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT** (this "Assignment"), effective as of July 23, 2019 (the "Effective Date"), is by and between Cipla USA, Inc., a Delaware corporation ("Assignee") and Achaogen, Inc., a Delaware corporation ("Assignor").

### WITNESSETH:

WHEREAS, pursuant to the terms and subject to the conditions of the Asset Purchase Agreement, dated June 20, 2019, as amended (the "Asset Purchase Agreement"), between Assignee and Assignor, Assignor has agreed to sell to Assignee, and Assignee has agreed to purchase from Assignor, among other things, the Purchased Assets; and

WHEREAS, pursuant to the Asset Purchase Agreement, Assignor desires to sell, assign, convey, deliver and transfer, free from all encumbrances, the entire right, title and interest in, to and under all of the Intellectual Property included in the Purchased Assets, including the Intellectual Property set forth on Exhibit A hereto (the "Assigned IP"), to Assignee and Assignee desires to acquire the entire right, title and interest in, to and under such Assigned IP. For the avoidance of doubt, Assigned IP includes the patent and trademark applications listed on Exhibit A as well as any application(s) for patent(s) or trademark(s) of the United States or other countries claiming priority to, and/or the benefit of, these applications, including any substitute application(s), division(s), continuation(s), continuation(s)-in-part, national or regional phase applications, and any patent(s) or trademark(s) of the United States or other countries that may be granted for or on any application for patent(s) or trademark(s), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s) or trademark(s).

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and as more fully set forth in the Asset Purchase Agreement and subject to the terms and conditions therein, the parties hereto, intending to be legally bound, hereby agree as follows:

1. Unless otherwise defined herein, all capitalized terms used herein shall have the meanings ascribed to such terms in the Asset Purchase Agreement.

2. Assignor hereby irrevocably sells, assigns, conveys, delivers and transfers to Assignee the entire right, title and interest in, to and under, free from all encumbrances, (i) the Assigned IP, together with all goodwill associated therewith, in each case to be held and enjoyed by Assignee for its own use and enjoyment as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment and sale had not been made, including the right to file applications for patent(s) or trademark(s) of the United States or other countries, including all rights under the Hague convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all right to claim priority in any country of the world under the International Convention for the Protection of Industrial Property and under any other international arrangement to which the United States of America is or hereafter becomes a signatory (but not, for the avoidance of doubt, any Excluded Liability), (ii) all rights to sue, claim and recover for past, present and future

infringement, misappropriation, dilution or other violation of any Assigned IP, and (iii) all income, royalties, damages and payments now or hereafter due or payable with respect to any of the foregoing.

3. Concurrent with the execution of this Assignment, Assignor shall transfer any and all domain names and social media accounts, as well as any trade dress, copyrights in artwork, labels, packaging, and patient information leaflets, included in the Assigned IP from Assignor's account to Assignee's account (such that Assignee will be listed as the registrant and/or owner of such domain names and social media accounts in the applicable registrar) and shall deliver to Assignee all necessary Auth-Info codes and all other required passwords necessary to unlock and control such domain names and social media accounts.

4. Upon the reasonable request by Assignee, Assignor shall execute all documents and take all actions as may be necessary or desirable to enable Assignee (or its Affiliate(s), as applicable) to prosecute, perfect, enforce, defend, register and/or record its right, title and interest in, to and under the Assigned IP, in each case, without further compensation but at the expense of Assignee. In the event that Assignor fails to execute any such document or take any such action as set forth in the preceding sentence, Assignor hereby designates Assignee (or its Affiliate(s), as applicable) as Assignor's agent, and hereby grants to Assignee (or its Affiliate(s), as applicable) a power of attorney with full power of substitution, which power of attorney shall be deemed coupled with an interest, for the purpose of executing such documents or taking such actions.

5. Assignor hereby authorizes and requests the officials of the United States Copyright Office and the United States Patent and Trademark Office, and the corresponding entities or agencies in any applicable foreign jurisdiction, to record and register Assignee (or its Affiliate(s), as applicable) as assignee and owner of the entire right, title and interest in, to and under the Assigned IP.

6. As soon as practicable after execution of this Assignment, Assignor shall, at the cost and expense of the Assignee, use diligent efforts to support transition of the assigned intellectual property from Assignor to Assignee through legal counsel at Cooley LLP, Morrison & Foerster LLP and Reed Smith LLP, who the Assignor has engaged for acquisition and maintenance of the Intellectual Property, and instruct such legal counsel to cooperate as appropriate with the Assignee in furtherance of the activities contemplated in the Asset Purchase Agreement and this Assignment. Assignor shall also use diligent effort to instruct any inventors and other employees who are under control of the Assignor to cooperate with the Assignee in furtherance of the activities contemplated in the Asset Purchase Agreement and this Assignment, including as appropriate any signatures, oaths, or declarations Assignee may request to file, prosecute, record, or transfer of the Assigned IP and to cooperate with and assist the Assignee in any litigation or other legal proceedings involving the Assigned IP.

7. This Assignment shall be governed by, and construed in accordance with, the laws of the State of Delaware without regard to the choice of law principles thereof. This Assignment is binding upon, and inures to the benefit of, the parties hereto and their respective legal representatives, successors and assigns. No waiver, modification or change of any

provision of this Assignment shall be valid unless in writing and signed by the party against whom such claimed waiver, modification or change is sought to be enforced.

8. This Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Assignment delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Assignment.

[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, the parties hereto, through their authorized representatives, have caused this Assignment to be duly executed and delivered as of the Effective Date.

**AS ASSIGNOR:**

**ACHAOGEN, INC.**

By:   
Name: Blake Wise  
Title: Chief Executive Officer

STATE OF )  
                                  ) ss  
COUNTY OF )

On the \_\_\_\_ day of \_\_\_\_\_, \_\_\_\_\_, before me personally came \_\_\_\_\_, who is personally known to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and did depose and say to me that he or she executed the same in his or her capacity as \_\_\_\_\_ of \_\_\_\_\_, the entity described in and which executed the foregoing instrument, and that he or she executed and delivered said instrument pursuant to authority given by the board of directors of such entity (or other applicable authority of such entity).

\_\_\_\_\_  
Notary Public

(PLACE STAMP AND SEAL ABOVE)

See Attached California  
All-Purpose  
Acknowledgment

*[Signature Page to Intellectual Property Assignment-Plazomicin]*

**CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT**

**CIVIL CODE § 1189**

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California )  
County of San Francisco )


On 8TH JULY 2019 before me, JAY G. PATEL, NOTARY PUBLIC  
Date Here Insert Name and Title of the Officer

personally appeared BLAKE WISE  
Name(s) of Signer(s)

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.



Signature [Handwritten Signature]  
Signature of Notary Public

Place Notary Seal Above

**OPTIONAL**

Though this section is optional, completing this information can deter alteration of the document or fraudulent reattachment of this form to an unintended document.

**Description of Attached Document**

Title or Type of Document: \_\_\_\_\_ Document Date: \_\_\_\_\_  
Number of Pages: \_\_\_\_\_ Signer(s) Other Than Named Above: \_\_\_\_\_

**Capacity(ies) Claimed by Signer(s)**

Signer's Name: \_\_\_\_\_ Signer's Name: \_\_\_\_\_  
 Corporate Officer -- Title(s): \_\_\_\_\_  Corporate Officer -- Title(s): \_\_\_\_\_  
 Partner --  Limited  General  Partner --  Limited  General  
 Individual  Attorney in Fact  Individual  Attorney in Fact  
 Trustee  Guardian or Conservator  Trustee  Guardian or Conservator  
 Other: \_\_\_\_\_  Other: \_\_\_\_\_  
Signer Is Representing: \_\_\_\_\_ Signer Is Representing: \_\_\_\_\_

IN WITNESS WHEREOF, the parties hereto, through their authorized representatives, have caused this Assignment to be duly executed and delivered as of the Effective Date.

**AS ASSIGNEE:**

**CIPLA USA INC.**

By: \_\_\_\_\_  
 Name: Nikhil Lalwani  
 Title: CEO - Cipla USA

DocuSigned by:  
*Nikhil Lalwani*  
 76F988D8A5CB45E...

STATE OF \_\_\_\_\_ )  
 ) ss  
 COUNTY OF \_\_\_\_\_ )

On the \_\_\_\_ day of \_\_\_\_\_, \_\_\_\_\_, before me personally came \_\_\_\_\_, who is personally known to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and did depose and say to me that he or she executed the same in his or her capacity as \_\_\_\_\_ of \_\_\_\_\_, the entity described in and which executed the foregoing instrument, and that he or she executed and delivered said instrument pursuant to authority given by the board of directors of such entity (or other applicable authority of such entity).


\_\_\_\_\_  
 Notary Public

(PLACE STAMP AND SEAL ABOVE)



[Signature Page to Intellectual Property Assignment-Plazomicin]








**EXHIBIT A**  
**ASSIGNED IP**










## II. TRADEMARKS

TM Record	TM/AN/RN/ Disclaimer	Status/Key Dates	Full Goods/Services	Owner/Designations
US Federal Q1 uf 3	Design Only  SN: 87929555	Published March 26, 2019 Filed: May 21, 2018	(Int'l Class: 05) antibiotics	Achaogen, Inc. (Delaware Corp.) 1 Tower Place, Suite 300 South San Francisco California 94080
US Federal Q1 uf 4	Design Only  SN: 87930012	Published March 26, 2019 Filed: May 21, 2018	(Int'l Class: 05) antibiotics	Achaogen, Inc. (Delaware Corp.) 1 Tower Place, Suite 300 South San Francisco California 94080




TM Record	TM/AN/RN/ Disclaimer	Status/Key Dates	Full Goods/Services	Owner/Designations
US Federal Q1 uf 5	ZEMDRI RN: 5661889 SN: 87080092	Registered January 22, 2019 Int'l Class: 05 First Use: July 17, 2018 Filed: June 22, 2016	(Int'l Class: 05) Antibiotics	Achaogen, Inc. (Delaware Corp.) 1 Tower Place, Suite 300 South San Francisco California 94080
US Federal Q1 uf 6	ZEMDRI and Design  SN: 87929654	Published March 26, 2019 Filed: May 21, 2018	(Int'l Class: 05) antibiotics	Achaogen, Inc. (Delaware Corp.) 1 Tower Place, Suite 300 South San Francisco California 94080
US Federal Q1 uf 7	ZEMDRI and Design  SN: 87930066	Published March 26, 2019 Filed: May 21, 2018	(Int'l Class: 05) antibiotics	Achaogen, Inc. (Delaware Corp.) 1 Tower Place, Suite 300 South San Francisco California 94080
Canada Q1 ca 9	Design Only  AN: 1931696	Canada Filed Last Status Received: Pending Application November 27, 2018 Office Status: Filing date accorded Filed: November 21, 2018	(Int'l Class: 05) Goods: (1) Antibiotics	Achaogen, Inc. 1 Tower Place, Suite 300 South San Francisco, CA 94080, United States of America
Canada Q1 ca 10	Design Only	Canada Filed Last Status Received: Pending Application November 27, 2018 Office Status: Filing date accorded Filed: November 21, 2018	(Int'l Class: 05) Goods: (1) Antibiotics	Achaogen, Inc. 1 Tower Place, Suite 300 South San Francisco, CA 94080, United States of America

TM Record	TM/AN/RN/ Disclaimer	Status/Key Dates	Full Goods/Services	Owner/Designations
Canada Q1 ca 11	 XEMDRO AN: 1812517	Canada Allowed Last Status Received: Application pending publication August 3, 2018 Office Status: Status: Application published Filed: December 5, 2016	(Int'l Class: 05) Goods: (1) Antibiotics	Achaogen, Inc. 7000 Shoreline Court, Suite 371 South San Francisco, CA 94080, United States of America
Canada Q1 ca 12	ZEMDRI AN: 1812518	Canada Allowed Last Status Received: Application pending publication August 3, 2018 Office Status: Application published Filed: December 5, 2016	(Int'l Class: 05) Goods: (1) Antibiotics	Achaogen, Inc. 7000 Shoreline Court, Suite 371 South San Francisco, CA 94080, United States of America
Canada Q1 ca 13	 ZEMDRI AN: 1931698	Canada Filed Last Status Received: Pending Application November 27, 2018 Office Status: Filing date accorded Filed: November 21, 2018	(Int'l Class: 05) Goods: (1) Antibiotics	Achaogen, Inc. 1 Tower Place, Suite 300 South San Francisco, CA 94080, United States of America
Canada Q1 ca 14	ZEMDRI and Design	Canada Filed Last Status Received: Pending Application November 27, 2018	(Int'l Class: 05) Goods: (1) Antibiotics	Achaogen, Inc. 1 Tower Place, Suite 300 South San Francisco, CA 94080, United States of America

TM Record	TM/AN/RN/ Disclaimer	Status/Key Dates	Full Goods/Services	Owner/Designations
Mexico Q1 mx 16	 <p>AN: 1931703</p>	Office Status: Filing date accorded Filed: November 21, 2018	(Translation) (Int'l Class: 05) Antibiotics.	ACHAOGEN, INC. 1 TOWER PLACE NUM. EXT. SUITE 300, 94080, SOUTH SAN FRANCISCO, CA, United States of America
Mexico Q1 mx 17	 <p>AN: M2152428</p>	Mexico Published Last Status Received: Published Filed: November 20, 2018	(Translation) (Int'l Class: 05) Antibiotics.	ACHAOGEN, INC. TOWER PLACE NUM. EXT. 1 NUM. INT. SUITE 300, 94080, SOUTH SAN FRANCISCO, CA, United States of America
Mexico Q1 mx 18	 <p>AN: M2153909</p>	Mexico Published Last Status Received: Published Filed: November 20, 2018	(Translation) (Int'l Class: 05) Antibiotics.	ACHAOGEN, INC. SHORELINE COURT NUM. EXT. 7000 NUM. INT. SUITE 371, 94080, SOUTH SAN FRANCISCO, CA., United States of America
Mexico Q1 mx 19	 <p>AN: M1831148</p>	Mexico Registered Last Status Received: Registered Filed: December 9, 2016	(Translation) (Int'l Class: 05) Antibiotics.	ACHAOGEN, INC. SHORELINE COURT NUM. EXT. 7000 NUM. INT. SUITE 371, 94080, SOUTH SAN FRANCISCO, CA., United

TM Record	TM/AN/RN/ Disclaimer	Status/Key Dates	Full Goods/Services	Owner/Designations
Mexico Q1 mx 20	ZEMDR1 and Design  AN: M2153892	Mexico Published Last Status Received: Published Filed: November 20, 2018	(Translation) (Int'l Class: 05) Antibiotics.	ACHAOGEN, INC. TOWER PLACE NUM. EXT. 1 NUM. INT. SUITE 300, 94080, SOUTH SAN FRANCISCO, CA, United States of America
Mexico Q1 mx 21	ZEMDR1 and Design  AN: M2156856	Mexico Published Last Status Received: Published Filed: November 20, 2018	(Translation) (Int'l Class: 05) Antibiotics.	ACHAOGEN, INC. TOWER PLACE NUM. EXT. 1 NUM. INT. SUITE 300, 94080, SOUTH SAN FRANCISCO, CA, United States of America
WIPO Q1 wo 23	Design Only  RN: 1441507	International Registered Last Status Received: Registered April 15, 2019 Registered: November 20, 2018 Expiration Date: November 20, 2028	(Int'l Class: 05) Antibiotics.	Achaogen, Inc. 1 Tower Place, Suite 300 South San Francisco CA 94080, United States of America Claimed Countries: Madrid Protocol: Australia, European Union, Israel, Japan, Mexico, Switzerland, Turkey, United Kingdom <sup>1</sup>
WIPO Q1 wo 24	Design Only	International Registered Last Status Received: Registered March 26, 2019 Registered: November 20, 2018 Expiration Date: November 20,	(Int'l Class: 05) Antibiotics.	Achaogen, Inc. 1 Tower Place, Suite 300 South San Francisco CA 94080, United States of America Claimed Countries: Madrid Protocol: Australia, European Union, Israel,



<sup>1</sup> For the avoidance of doubt, this transfer does not include the transfer of trademark rights in China, Hong Kong, Taiwan, or Macau.

TM Record	TM/AN/RN/ Disclaimer	Status/Key Dates	Full Goods/Services	Owner/Designations
WIPO Q1 wo 25	 RN: 1442826	2028  International Registered Last Status Received: Registered November 20, 2018 Expiration Date: November 20, 2028	(Int'l Class: 05) Antibiotics.	Achaogen, Inc.: 1 Tower Place, Suite 300 South San Francisco CA 94080, United States of America Claimed Countries: Madrid Protocol: Australia, European Union, Israel, Japan, Mexico, Switzerland, Turkey, United Kingdom <sup>3</sup>
WIPO Q1 wo 26	 RN: 1442745	International Registered Last Status Received: Registered April 2, 2019 Registered: November 20, 2018 Expiration Date: November 20, 2028	(Int'l Class: 05) Antibiotics.	Achaogen, Inc.: 1 Tower Place, Suite 300 South San Francisco CA 94080, United States of America Claimed Countries: Madrid Protocol: Australia, European Union, Israel, Japan, Mexico, Switzerland, Turkey, United Kingdom <sup>4</sup>
Iceland Q1 Is 28	 RN: 1443260	Iceland Registered Last Status Received: Registered Filed: November 15, 2017 Registered: November 30, 2017 Expiration Date: November 30, 2027	(Translation) (Int'l Class: 05) Antibiotics.	Nafn: Achaogen, Inc., a corporation of the State of Delaware, United States of America Heimilistfang: 1 Tower Place, Suite 300, South San Francisco, California 94080, US, US, United States of America
Norway	ZEMDR I	Norway	(Translation)	Achaogen, Inc.: 1 Tower Place,



<sup>2</sup> For the avoidance of doubt, this transfer does not include the transfer of trademark rights in China, Hong Kong, Taiwan, or Macau.

<sup>3</sup> For the avoidance of doubt, this transfer does not include the transfer of trademark rights in China, Hong Kong, Taiwan, or Macau.



<sup>4</sup> For the avoidance of doubt, this transfer does not include the transfer of trademark rights in China, Hong Kong, Taiwan, or Macau.


TM Record	TM/AN/RN/ Disclaimer	Status/Key Dates	Full Goods/Services	Owner/Designations
Q1 no 29	RN: 297414 AN: 201715319	Registered Last Status Received: Registered April 11, 2018 Filed: November 16, 2017 Expiration Date: November 16, 2027	(Int'l Class: 05) Antibiotics.	Suite 300, CA94080, SOUTH SAN FRANCISCO, United States of America
Switzerland Q1 ch 30	XEMDR0 RN: 699873 AN: 64827/2016	Switzerland Registered Last Status Received: Registered Filed: December 5, 2016 Registered: March 14, 2017 Expiration Date: December 5, 2026	(Translation) (Int'l Class: 05) Antibiotics.	Achaogen, Inc: 7000 Shoreline Court Suite 371, 94080 South San Francisco, California, United States of America
Switzerland Q1 ch 31	ZEMDR1 RN: 699961 AN: 64828/2016	Switzerland Registered Last Status Received: Registered Filed: December 5, 2016 Registered: March 16, 2017 Expiration Date: December 5, 2026	(Translation) (Int'l Class: 05) Antibiotics.	Achaogen, Inc: 7000 Shoreline Court Suite 371, 94080 South San Francisco, California, United States of America
Turkey Q1 tr 33	Design Only  AN: 2019/01458	Turkey Published Last Status Received: Published Filed: November 20, 2018	(Int'l Class: 05) Antibiotics.	ACHAOGEN, INC. 1 Tower Place, Suite 300 South San Francisco CA 94080, United States of America
Turkey Q1 tr 34	Design Only 	Turkey Published Last Status Received: Published Filed: November 20, 2018	(Int'l Class: 05) Antibiotics.	ACHAOGEN, INC. 1 Tower Place, Suite 300 South San Francisco CA 94080, United States of America





TM Record	TM/AN/RN/ Disclaimer	Status/Key Dates	Full Goods/Services	Owner/Designations
Turkey Q1 tr 35	Xendro  AN: 2016/99237	Turkey Published Last Status Received: Published Filed: December 8, 2016	(Translation) (Int'l Class: 05) antibiotics	ACHAOGEN, INC. 7000 Shoreline Court, Suite 371, South San Francisco, California 94080, United States of America
Turkey Q1 tr 36	zendri  RN: 2016 99232 AN: 2016/99232	Turkey Registered Last Status Received: Registered Filed: December 8, 2016 Registered: October 3, 2017	(Translation) (Int'l Class: 05) antibiotics.	ACHAOGEN, INC. 7000 Shoreline Court, Suite 371, South San Francisco, California 94080, United States of America
United Kingdom Q1 gb 38	XEMDRO RN: 3172211 AN: 3172211	United Kingdom Registered Last Status Received: Registered September 30, 2016 Filed: June 30, 2016 Expiration Date: June 30, 2026	(Int'l Class: 05) Antibiotics.	Achaogen, Inc. (Company or Organisation Delaware) 7000 Shoreline Court, Suite 371, 94080, South San Francisco, California, United States of America
United Kingdom Q1 gb 39	ZEMDRI RN: 3172247 AN: 3172247	United Kingdom Registered Last Status Received: Registered September 30, 2016 Filed: June 30, 2016 Expiration Date: June 30, 2026	(Int'l Class: 05) Antibiotics.	Achaogen, Inc. (Company or Organisation Delaware) 7000 Shoreline Court, Suite 371, 94080, South San Francisco, California, United States of America

TM Record	TM/AN/RN/ Disclaimer	Status/Key Dates	Full Goods/Services	Owner/Designations
European Union (EUTM) Q1 eu 41	XEMDR0 RN: 015595499 AN: 015595499	European Union Registered Last Status Received: Registered October 19, 2016 Filed: June 29, 2016 Registered: October 17, 2016 Expiration Date: June 29, 2026	(Int'l Class: 05) Antibiotics.	Achaogen, Inc. (Corporation Delaware) 7000 Shoreline Court, Suite 371, 94080, South San Francisco, California, United States of America
European Union (EUTM) Q1 eu 42	ZEMDR1 RN: 015595515 AN: 015595515	European Union Registered Last Status Received: Registered October 19, 2016 Filed: June 29, 2016 Registered: October 17, 2016 Expiration Date: June 29, 2026	(Int'l Class: 05) Antibiotics.	Achaogen, Inc. (Corporation Delaware) 7000 Shoreline Court, Suite 371, 94080, South San Francisco, California, United States of America
Israel Q1 il 44	XEMDR0 AN: 290115	Israel Registered Last Status Received: Registered Filed: December 4, 2016 Registered: April 9, 2018 Expiration Date: December 4, 2026	(Int'l Class: 05) Antibiotics; all included in class 5.	Achaogen, Inc. 7000 Shoreline Court, Suite 371, South San Francisco, California, 94080, U.S.A., United States of America
Israel Q1 il 45	ZEMDR1 AN: 290114	Israel Registered Last Status Received: Registered Filed: December 4, 2016 Registered: April 9, 2018 Expiration Date: December 4, 2026	(Int'l Class: 05) Antibiotics; all included in class 5.	Achaogen, Inc. 7000 Shoreline Court, Suite 371, South San Francisco, California, 94080, U.S.A., United States of America
South Africa Q1 za 47	ZEMDR1 AN: 2017/33426	South Africa Published Last Status Received: Published Filed: November 16, 2017	(Int'l Class: 05) Antibiotics	Achaogen, Inc. a corporation of the State of Delaware 1 Tower Place, Suite 300, South San Francisco, California, 94080, United States of America
Australia Q1 au 49	Design Only	Australia Filed Last Status Received: Pending Application Office Status: Published.	(Int'l Class: 05) Antibiotics.	Achaogen, Inc. United States of America

TM Record	TM/AN/RN/ Disclaimer	Status/Key Dates	Full Goods/Services	Owner/Designations
Australia Q1 au 50	 <p>AN: 1981466 Disclaimer: The mark consists of stylized human figure stepping out of a ring.</p>	<p>Awaiting examination Filed: November 20, 2018 Int'l Reg Date: November 20, 2018</p>		Achaogen, Inc. United States of America
Australia Q1 au 50	 <p>AN: 1980719 Disclaimer: The mark consists of stylized human figure in the color purple stepping out of a ring in the color green. The color(s) Purple and Green is/are claimed as a feature of the mark. The mark consists of stylized human figure in the color purple stepping out of a ring in the color green.</p>	<p>Australia Filed Last Status Received: Pending Application Office Status: Published: Awaiting examination Filed: November 20, 2018 Int'l Reg Date: November 20, 2018</p>	(Int'l Class: 05) Antibiotics.	Achaogen, Inc. incorporated in the State of Delaware incorporated in the State of Delaware United States of America
Australia Q1 au 51	<p>XEMDRO RN: 1813625 AN: 1813625 Disclaimer: Convention priority claimed: 22 June 2016; United States of America, No. 87/080087 in respect of ALL ITEMS IN THIS CLASS ARE CLAIMED IN THE CONVENTION</p>	<p>Australia Registered Last Status Received: Registered Office Status: Registered: Registered/protected Filed: December 5, 2016 Registered: December 5, 2016 Expiration Date: December 5, 2026</p>	(Int'l Class: 05) Antibiotics	Achaogen, Inc. incorporated in the State of Delaware incorporated in the State of Delaware United States of America

TM Record	TM/AN/RN/ Disclaimer	Status/Key Dates	Full Goods/Services	Owner/Designations
Australia Q1 au 52	ZEMDRI RN: 1813626 AN: 1813626 Disclaimer: Convention priority claimed: 22 June 2016, United States of America, No. 87/080092 in respect of ALL ITEMS IN THIS CLASS ARE CLAIMED IN THE CONVENTION APPLICATION in class 5.*	Australia Registered Last Status Received: Registered Office Status: Registered: Registered/protected Filed: December 5, 2016 Registered: December 5, 2016 Expiration Date: December 5, 2026	(Int'l Class: 05) Antibiotics	Achaogen, Inc. incorporated in the State of Delaware incorporated in the State of Delaware United States of America
Australia Q1 au 53	ZEMDRI and Design AN: 1982221 Disclaimer: The mark consists of stylized human figure in the color purple stepping out of a ring in the color green all above the word ZEMDRI in the color purple. The color(s) green and purple is/are claimed as a feature of the mark. The mark consists of stylized human figure in the color purple stepping out of a ring in the color green all above the word ZEMDRI in the color purple.	Australia Filed Last Status Received: Pending Application Office Status: Published: Awaiting examination Filed: November 20, 2018 Int'l Reg Date: November 20, 2018	(Int'l Class: 05) Antibiotics.	Achaogen, Inc. United States of America
Australia Q1 au 54	ZEMDRI and Design  AN: 1981456 Disclaimer: The mark consists of stylized human figure stepping out of a ring all above the word ZEMDRI.	Australia Filed Last Status Received: Pending Application Office Status: Published: Awaiting examination Filed: November 20, 2018 Int'l Reg Date: November 20, 2018	(Int'l Class: 05) Antibiotics.	Achaogen, Inc. United States of America
India	ZEMDRI	DELHI - Filed	(Int'l Class: 05)	ACHAOGEN, INC. Body

TM Record	TM/AN/RN/ Disclaimer	Status/Key Dates	Full Goods/Services	Owner/Designations
Q1 in 60	AN: 3681462	Last Status Received: Objection pending Filed: November 18, 2017	antibiotics.	Incorporate 1 Tower Place Suite 300 South San Francisco, California 94080 United States of America, United States of America
New Zealand Q1 nz 62	XEMDR0 RN: 1056597 AN: 1056597	New Zealand Registered Last Status Received: Registered June 7, 2017 Office Status: Registered Filed: December 5, 2016 Expiration Date: June 22, 2026	(Int'l Class: 05) Antibiotics.	Achaogen, Inc. a corporation of the State of Delaware 7000 Shoreline Court, Suite 371 California 94080 South San Francisco, United States of America
New Zealand Q1 nz 63	ZEMDR1 RN: 1056598 AN: 1056598	New Zealand Registered Last Status Received: Registered June 7, 2017 Office Status: Registered Filed: December 5, 2016 Expiration Date: June 22, 2026	(Int'l Class: 05) Antibiotics.	Achaogen, Inc. a corporation of the State of Delaware 7000 Shoreline Court, Suite 371 California 94080 South San Francisco, United States of America
Republic of Korea Q1 kr 64	ZEMDR1 	Republic of Korea Registered Last Status Received: Registered Filed: December 29, 2017 Registered: August 22, 2018	(Translation) (Int'l Class: 05) Antibiotics	ACHAOGEN, INC. 아카오젠, 인코포레이티드 * Tower Place, Suite ***, South San Francisco, California ***** United States of America, United States of America
Singapore Q1 sg 66	No Text Elements  AN: 40201722640X	Singapore Published Last Status Received: Published April 6, 2018 Filed: November 16, 2017	(Int'l Class: 05) Antibiotics.	Achaogen, Inc. 1 Tower Place, Suite 300, South San Francisco, California 94080, United States of America, Delaware, United States of America, United States of America

TM Record	TM/AN/RN/ Disclaimer	Status/Key Dates	Full Goods/Services	Owner/Designations
Argentina Q1 at 75	XEMDR0 RN: 2948099 AN: 3565052	Argentina Registered Last Status Received: Registered Filed: December 7, 2016 Registered: August 7, 2018 Expiration Date: August 7, 2028	(Translation) (Int'l Class: 05) Only: antibiotics.	ACHAOGEN, INC. 7000 SHORELINE COURT SUITE 371, SOUTH SAN FRANCISCO CP, 94080, United States of America
Argentina Q1 at 76	XEMDR1 RN: 2928489 AN: 3565053	Argentina Registered Last Status Received: Registered Filed: December 7, 2016 Registered: March 9, 2018 Expiration Date: March 9, 2028	(Translation) (Int'l Class: 05) Only: antibiotics.	ACHAOGEN, INC. 7000 SHORELINE COURT SUITE 371, SOUTH SAN FRANCISCO CP, 94080, United States of America
Brazil Q1 br 78	XEMDR0 RN: 912032103 AN: 912032103	Brazil Registered Last Status Received: Registered Filed: December 9, 2016 Registered: October 2, 2018 Expiration Date: October 2, 2028	(Translation) (Int'l Class: 05) antibiotics.	ACHAOGEN, INC.
Brazil Q1 br 79	XEMDR1 RN: 912032081 AN: 912032081	Brazil Registered Last Status Received: Registered Filed: December 9, 2016 Registered: October 2, 2018 Expiration Date: October 2, 2028	(Translation) (Int'l Class: 05) antibiotics.	ACHAOGEN, INC.
Colombia Q1 co 80	XEMDR0 RN: 570091 AN: SD20160053447	Colombia Registered Last Status Received: Registered Filed: December 12, 2016 Registered: June 9, 2017 Expiration Date: June 9, 2027	(Translation) (Int'l Class: 05) ]: Antibiotics.	ACHAOGEN, INC 7000 SHORELINE COURT, SUITE 371, SAN FRANCISCO CALIFORNIA; US, United States of America
Colombia Q1 co 81	XEMDR1 RN: 570163 AN: SD20160053449	Colombia Registered Last Status Received: Registered Filed: December 12, 2016 Registered: June 12, 2017 Expiration Date: June 12, 2027	(Translation) (Int'l Class: 05) ]: Antibiotics.	ACHAOGEN, INC 7000 SHORELINE COURT, SUITE 371, SAN FRANCISCO CALIFORNIA; US, United States of America

Country	Trademark	Application No.	Filing Date	Registration No.	Registration Date	Status	Class	Renewal Date
JAPAN	ZEMDRI	2016-137421	12/6/2016	5943897	4/28/2017	REGISTERED	5	04/28/2027 RENEWAL
RUSSIA	ZEMDRI	2016746344	12/7/2016	2016746344	9/9/2017	REGISTERED	5	12/07/2026 RENEWAL
JAPAN	XEMDRO	2016-137419	12/6/2016	5943896	4/28/2017	REGISTERED	5	04/28/2027 RENEWAL
RUSSIA	XEMDRO	2016746300	12/7/2016	2016746300	8/30/2017	REGISTERED	5	12/07/2026 RENEWAL
UNITED STATES	XEMDRO	87/080,087	6/22/2016			ABANDONED	5	
UNITED STATES	ZEMDRO	87/080,094	6/22/2016			ABANDONED	5	